Clinicopathological findings of chronic rejection in a face grafted patient

Transplantation

Volumn 99, Issue 12, 2015, Pages 2644-2650

  Petruzzo, Palmina ^a,b   Kanitakis, Jean ^a   Testelin, Sylvie ^c   Pialat, Jean Baptiste ^a   Buron, Fanny ^a   Badet, Lionel ^a   Thaunat, Olivier ^a,d   Devauchelle, Bernard ^c   Morelon, Emmanuel ^a,d  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRABECTEDIN; VINCRISTINE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CHRONIC GRAFT REJECTION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FACE EDEMA; FACE ERYTHEMA; FACIAL TRANSPLANTATION; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMAN TISSUE; HYPOPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER TUMOR; MALE; MOUTH ULCER; MUSCLE TUMOR; PATIENT MONITORING; PRIORITY JOURNAL; SKIN BIOPSY; TELANGIECTASIA; ALLOGRAFT; BIOPSY; CHRONIC DISEASE; GRAFT SURVIVAL; PATHOLOGY; PROCEDURES;

ADULT; ALLOGRAFTS; BIOPSY; CHRONIC DISEASE; FACIAL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 84945463970     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000765     Document Type: Article

References (25)

1. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet. 1999; 353(9161): 1315-1320.
2. Devauchelle B, Badet L, Lengelé B, et al. First human face allograft: early report. Lancet. 2006; 368(9531): 203-209.
3. Petruzzo P, Dubernard JM. The International Registry on Hand and Composite Tissue allotransplantation. Clin Transpl. 2011; 247-1320.
4. Khalifian S, Brazio PS, Mohan R, et al. Facial transplantation: the first 9 years. Lancet. 2014; 384(9960): 2153-2163.
5. Cendales L, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant. 2008; 8: 1396-1400.
6. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14(2): 272-283.
7. Unadkat J, Schneeberger S, Horibe E, et al. Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. Am J Transplant. 2010; 10: 251-261.
8. Mundinger GS, Munivenkatappa R, Drachenberg CB, et al. Histopathology of chronic rejection in a nonhuman primatemodel of vascularized composite allotransplantation. Transplantation. 2013; 95: 1204-1210.
9. Kaufman CL, Ouseph R, Blair B, et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant. 2012; 12: 1004-1016.
10. Kanitakis J, Karayannopoulou G, Lanzetta M, et al. Graft vasculopathy in the skin of a human hand-allograft: implications for diagnosis of rejection of vascularized composite allografts. Transpl Int. 2014; 27: e118-e123.
11. Petruzzo P, Kanitakis J, Badet L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant. 2011; 11(4): 808-816.
12. Neumann UP, Langrehr JM, Nehaus P. Chronic rejection after liver transplantation. Graft. 2002; 5: 102.
13. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006; 81(5): 643-654.
14. Suzuki J, Isobe M, Morishita R, et al. Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments. Circ J. 2010; 74: 233-239.
15. Schmauss D, WeisM. Cardiac allograft vasculopathy: recent developments. Circulation. 2008; 117: 2131-2141.
16. Thaunat O, Louedec L, Graff-Dubois S, et al. Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis. Transplantation. 2008; 85(2): 281-289.
17. Conrad A, Brunet AS, Hervieu V, et al. Epstein-Barr virusassociated smooth muscle tumors in a composite tissue allograft and a pediatric liver transplant recipient. Transpl Infect Dis. 2013; 15(5): E182-E186.
18. Hymes SR, Turner MI, Champlin RE, et al. Cutaneous manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2006; 12: 1101-1113.
19. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versushost- disease. HematologyAmSocHematol Educ Program. 2008; 134-141.
20. Rodgers CJ, Burge S, Scarisbrick J, et al. More than skin deep? Emerging therapies for chronic cutaneous GVHD. Bone Marrow Transplant. 2013; 48: 323-327.
21. Thaunaut O. Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl Immunol. 2012; 26(2-3): 101-106.
22. Chandraker A, Arscott R, Murphy GF, et al. Themanagement of antibodymediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant. 2014; 14(6): 1446-1452.
23. Weissenbacher A, Hautz T, Zelger B, et al. Antibody-mediated rejection in hand transplantation. Transpl Int. 2014; 27(2): e13-e17.
24. Thaunat O, Field AC, Dai J, et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci U S A. 2005; 102(41): 14723-14728.
25. Martin L, Guignier F, Mousson C, et al. Detection of donor-specific anti- HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation. 2003; 76(2): 395-400.